Myriad Genetics (NASDAQ: MYGN) Stock Upgrade: Piper Sandler Adjusts Rating Amidst Prenatal Business Sale
Piper Sandler upgraded Myriad Genetics (NASDAQ: MYGN) to Neutral from Underweight, setting a $5.00 price target. Myriad Genetics is selling its prenatal health testing business to Labcorp for $210.00 million in cash. This strategic divestiture is expected to improve Myriad Genetics' revenue…